AMSAMERICAN SHARED HOSPITAL SERVICES
Is American Shared Hospital Services struggling financially?
Yes, by its own account. American Shared Hospital Services told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
30/100
Fragile
- Sector
- Biotech/Pharma
- Market cap
- $10.0M
- Source filing
- 10-Q 14 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
31+ mo
Runs out some time after Jan 2029, raising nothing.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$6.5M
÷
Cash burned over the last 12 months
$2.1M
What American Shared Hospital Services told the SEC
…defaults thereunder, the Company would not have sufficient cash on hand to satisfy such accelerated payment obligations. As a result, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. To date, the Company has not negotiated a definitive extension and, if the Company is ultimately unable to do so, the Company’s liquidity will be adversely impacted and the Company’s…
AMERICAN SHARED HOSPITAL SERVICES, Form 10-Q, filed 14 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- Debt pressure is material Operating earnings cover only -2.7x the interest bill, so the interest is being met out of cash reserves rather than out of the business.
- Cash burn is narrowing It is spending 84% less cash per year than it was, so the runway above is lengthening rather than shortening.
Other Biotech/Pharma companies that filed the doubt
- QNCX Quince Therapeutics $34.5M
- ELAB PMGC Holdings $53.9M
- DERM Journey Medical $218.7M
- IBIO iBio $71.0M
- OKUR Onkure Therapeutics $159.6M
- ZBIO Zenas BioPharma $2.1B